Author: Tom Mirga

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

In Federal, Judicial, Pharma Industry, RegulatoryJanuary 14, 2021

The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications, …

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

In Federal, Judicial, Pharma IndustryJanuary 14, 2021

Tom Mirga

340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies. …

Nevada ADAP Postpones Controversial 340B Policy Change

In Regulatory, StateJanuary 14, 2021

Tom Mirga

Nevada’s AIDS Drug Assistance Program (ADAP) on Tuesday postponed “through April 1, 2021, if not longer,” a 340B program policy change strongly opposed by the state’s Ryan White CARES Act grantees. The state health department’s Division of Public and Behavioral …

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

In Federal, Judicial, Pharma Industry, RegulatoryJanuary 13, 2021

Tom Mirga

In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”

Please Login

…

HRSA Releases Details and FAQs About New 340B Dispute Resolution System

In Federal, RegulatoryJanuary 12, 2021

Tom Mirga

The U.S. Health Resources and Services Administration (HRSA) Tuesday afternoon posted a new webpage describing the steps health care providers and drug manufacturers must follow to invoke the 340B program’s new administrative dispute resolution (ADR) process. It simultaneously posted 11 …

340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor

In Federal, Other Industry, Pharma Industry, RegulatoryJanuary 12, 2021

Tom Mirga

Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen …

Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers

In Federal, Legislative, Pharma Industry, RegulatoryJanuary 12, 2021

Tom Mirga

The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition …

Nevada Ryan White Clinics Furious About State ADAP’s 340B Policy Change

In Regulatory, StateJanuary 12, 2021

Tom Mirga

Nevada Ryan White CARES Act grantees enrolled in 340B are strongly protesting a state AIDS Drug Assistance Program (ADAP) policy change that the clinics say will deprive them of 340B savings on drugs that pay for housing, transportation, and

…

340B Providers Welcome Democratic Control of Congress and White House

In UncategorizedJanuary 7, 2021

Tom Mirga

Although groups representing 340B providers will be measured in any public statements, they are elated by the Democratic sweep of the two U.S. Senate races in Georgia on Tuesday. With Raphael Warnock (D) and Jon Ossoff’s (D) victories, Democrats have

…

Chicago Tribune’s 340B Article Grabs Senior U.S. Senator’s and Governor’s Attention (Updated)

In UncategorizedJanuary 5, 2021

Tom Mirga

Please Login or Become a Paid Subscriber to View this Content

Chicago Tribune, one of the nation’s largest daily newspapers, yesterday published a front-page, nearly 2,000-word article about drug manufacturers’ denials of 340B pricing on medications

…